Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

METABOLIC DISEASES

Designer cytokine for the treatment of diabetes

Nature Metabolism volume 1, pages 933–934 (2019)Cite this article

Subjects

Findeisen et al. have engineered IC7Fc, a cytokine for the treatment of type 2 diabetes, that selectively activates beneficial metabolic pathways systemically and in metabolic tissues without promoting an inflammatory response.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: IC7Fc is an engineered chimera of IL-6 and CNTF.

References

  1. Nolan, C. J. & Prentki, M. Diab. Vasc. Dis. Res. 16, 118–127 (2019).

    Article  CAS  Google Scholar 

  2. Donath, M.Y., Dinarello, C.A. & Mandrup-Poulsen, T. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-019-0213-9 (2019).

  3. Findeisen, M. et al. Nature https://doi.org/10.1038/s41586-019-1601-9 (2019).

  4. Donath, M. Y. & Shoelson, S. E. Nat. Rev. Immunol. 11, 98–107 (2011).

    Article  CAS  Google Scholar 

  5. Pedersen, B. K. et al. Proc. Nutr. Soc. 63, 263–267 (2004).

    Article  CAS  Google Scholar 

  6. Ellingsgaard, H. et al. Nat. Med. 17, 1481–1489 (2011).

    Article  CAS  Google Scholar 

  7. Watt, M. J. et al. Nat. Med. 12, 541–548 (2006).

    Article  CAS  Google Scholar 

  8. Kallen, K. J. et al. J. Biol. Chem. 274, 11859–11867 (1999).

    Article  CAS  Google Scholar 

  9. Lehrskov, L. L. & Christensen, R. H. Semin. Immunopathol. 41, 491–499 (2019).

    Article  Google Scholar 

  10. Drucker, D. J. & Nauck, M. A. Lancet 368, 1696–1705 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland

    Marc Y. Donath

  2. Department of Biomedicine, University of Basel, Basel, Switzerland

    Marc Y. Donath

Authors
  1. Marc Y. Donath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Y. Donath.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Donath, M.Y. Designer cytokine for the treatment of diabetes. Nat Metab 1, 933–934 (2019). https://doi.org/10.1038/s42255-019-0130-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-019-0130-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing